Natus Medical Incorporated

Jeffries Global Healthcare

CONFERENCE

Tuesday June 6, 2017

2

Forward-Looking StatementsThis presentation contains forward-looking statements including statements regarding ourexpectations, beliefs, plans and intentions, which involve known and unknown risks,uncertainties, and other factors which may cause our actual results, performance, orachievements to be materially different from any future results, performance, orachievements expressed or implied by any forward looking statements. These statementsreflect our current views with respect to future events and are based on assumptions, andsubject to risks and uncertainties. Given these uncertainties, you should not place unduereliance on these forward-looking statements. We discuss many of these risks in greaterdetail in our filings with the SEC, which you should read carefully. You should listen to theinformation contained in this presentation completely with the understanding that ouractual future results may be materially different from what we expect, and from historicalresults and trends. We qualify all our forward-looking statements by these cautionarystatements. Natus disclaims any obligation to update information contained in any forward-looking statement.

Reconciliation of GAAP to non-GAAP results are contained in our press releases and SECfilings.

Natus is a leading provider of medical devices for the newborn care, hearing and neurologymarkets. Additional information about Natus Medical can be found at www.natus.com.

3

About Natus

Neurodiagnostics

Newborn Care

Otometrics

48%

31%

21%

EEGElectroencephalography

EMGElectromyography

Hearing Screening

Brain Injury

Phototherapy

Hearing Screening

Hearing Aid Fitting

Balance

Hearing Diagnostics

4

Revenue Growth: 10-YR CAGR ~ 19%Organic growth and acquisitions$ millions

$90

$292

$382

2006 2012 2016 2017 Guidance

Guidance

$505 –$510

5

Non-GAAP Operating Margin Growth

*Non-GAAP earnings excl. intangible amort., restructurings, and certain other one-time items. For more information, please see our periodic press releases and associated SEC filings at http://investor.natus.com.

9%

14%

16%

19%18%

15%

20%

2012 2013 2014 2015 2016 2017 Guidance GOAL

Otometrics Acquisition

6

$ millions

0.63

1.04

1.26

1.551.62

2012 2013 2014 2015 2016 2017 Guidance

Non-GAAP EPS Growth

Guidance

$1.70 –$1.75

*FY’17 guidance as of April 26, 2017. Non-GAAP earnings excl. intangible amort., restructurings, and certain other one-time items. For more information, please see our periodic press releases and associated SEC filings at http://investor.natus.com.

PhototherapyHearing Screening Brain Injury

NEWBORN CARE

8

Market Leader in Newborn CarePioneered newborn hearing screening

Worldwide Market Share

~70%

Hearing screening devices / disposables

Phototherapy

Services - Peloton

9

Peloton: Hearing Screening Service for Hospitals

• Opportunity to convert Natus Algo customers

• Hospital benefits

− Gain cost savings

− Eliminate screening management

Q1’14 Q4’16

0

127Hospitals

EEGElectroencephalography

EMGElectromyography

NEURODIAGNOSTICS

11

Market Leader in NeurodiagnosticsCompleted roll-up of fragmented market in 2012

Worldwide Market Share

~60%

EEG

EMG

Services - GND

*Worldwide market shares excludes Japanese market

12

Global Neurodiagnostics (GND)

• Provides in-home neurodiagnostic service

• Reduces overall payor cost by 50-65%

• Expanding in major U.S. markets

Entered market3 states

Growth into22 states

Q12015

Q42016

Growth into33 states

2017Goal

Hearing Diagnostics BalanceHearing ScreeningHearing Aid Fitting

OTOMETRICS

14

+A GLOBAL LEADER MARKET PRESENCE

• Newborn Hearing Screening

• Hearing diagnostics

• Balance assessment

• Hearing Aid Fitting

• Largest independent hearing aid fitting supplier

• Premium global brands

• Expanding margins as we complete integrations

15

Market Leader in AudiologyAcquired Otometrics January 2017

Hearing Screening

12%

Hearing Diagnostics

24%

Hearing Aid Fitting

40%

Balance11%

Supplies & Other

13%

% Revenue 2016 Hearing Screening

Hearing Aid Fitting

Balance Assessment

Hearing Diagnostics

16

% Revenue

-1%

10%

20%

Pre Acquisition 2017 2018

Otometrics Operating Margin Goals

17

% Annual Revenue

22%24% 24%

30%

Q1 Q2 Q3 Q4

Otometrics Revenue Cyclicality

18

2017 Guidance

Q2 2017 FY 2017

Consolidated Revenue $121M - $123M $505M - $510M

Non-GAAP EPS $0.32 - $0.34 $1.70 - $1.75

19

Natus Summary

• Leverage global marketing and distribution platform

• Targeted acquisitions with fiscal discipline

• Continued margin expansion and earnings growth

M A R K E T L E A D E R

Newborn Care AudiologyNeurodiagnostics

20